Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2017.1359537
Abstract: ABSTRACT Introduction: Rituximab, an anti-CD20 monoclonal antibody, is a key therapeutic in the treatment of B cell lymphomas and rheumatoid arthritis (RA). Global rates of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and RA are… read more here.
Keywords: rituximab; treatment; safety; rituximab biosimilar ... See more keywords
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155217731506
Abstract: Purpose The purpose of this study was to evaluate the in-use physicochemical and biological stability of the Sandoz rituximab biosimilar, marketed under the trade names Rixathon® and Riximyo® in the European Union, upon preparation for… read more here.
Keywords: infusion; rixathon riximyo; rituximab biosimilar; intravenous infusion ... See more keywords